A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Running, not enrolling · Phase 3

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Key facts

Study ID

NCT03052608

Run by

Pfizer

People needed

296

Starts

2017-04-27

Expected to finish

2028-12-31

Last updated by the study team

2025-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK-positive NSCLC; at least 1 extracranial measurable target lesion not previously irradiated. CNS metastases allowed if asymptomatic and not currently requiring corticosteroid treatment.
• Availability of an archival FFPE tissue specimen.
• No prior systemic NSCLC treatment.
• ECOG PS 0, 1, or 2.
• Age ≥18 years .
• Adequate Bone Marrow, Liver, Renal, Pancreatic Function
• Negative pregnancy test for females of childbearing potential

You may not qualify if…

• Spinal cord compression unless good pain control attained
• Major surgery within 4 weeks prior to randomization.
• Radiation therapy within 2 weeks prior to randomization, including stereotactic or partial brain irradiation. Whole brain irradiation within 4 weeks prior to randomization
• Active bacterial, fungal, or viral infection
• Clinically significant cardiovascular disease, active or within 3 months prior to enrollment. Ongoing cardiac dysrhythmias, uncontrolled atrial fibrillation, bradycardia or congenital long QT syndrome
• Predisposing characteristics for acute pancreatitis in the last month prior to randomization.
• History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease
• Active malignancy (other than NSCLC, non melanoma skin cancer, in situ cervical cancer, papillary thyroid cancer, LCIS/DCIS of the breast, or localized prostate cancer) within the last 3 years prior to randomization.
• Concurrent use of any of the following food or drugs within 12 days prior to the first dose of lorlatinib or crizotinib.
• known strong CYP3A inhibitors .
• known strong CYP3A inducers
• known P gp substrates with a narrow therapeutic index
• Concurrent use of CYP3A substrates with narrow therapeutic indices within 12 days prior to the first dose of lorlatinib or crizotinib.
• Other severe acute or chronic medical or psychiatric condition, including recent or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or interfere with the interpretation of study results
• Investigational site staff members directly involved in the conduct of the study and their family members, or Pfizer employees, including their family members, directly involved in the conduct of the study.
• Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.

Where it is running

• Florida Cancer Specialists — Brandon, Florida, United States
• Florida Cancer Specialists — Clearwater, Florida, United States
• Florida Cancer Specialists — Gainesville, Florida, United States
• Florida Cancer Specialists — Largo, Florida, United States
• Florida Cancer Specialists — Lecanto, Florida, United States
• Florida Cancer Specialists — Orange City, Florida, United States
• Florida Cancer Specialists — Orlando, Florida, United States
• Florida Cancer Specialists — Spring Hill, Florida, United States
• Florida Cancer Specialists — St. Petersburg, Florida, United States
• Florida Cancer Specialists — Tampa, Florida, United States
• Florida Cancer Specialists — Tavares, Florida, United States
• Florida Cancer Specialists — The Villages, Florida, United States
• Florida Cancer Specialists — Winter Park, Florida, United States
• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Ophthalmic Consultants of Boston Inc — Boston, Massachusetts, United States
• The William P. Beetham Eye Institute, Joslin Diabetes Center — Boston, Massachusetts, United States
• University of Rochester Cancer Center Pharmacy — Rochester, New York, United States
• University of Rochester Medical Center — Rochester, New York, United States
• Tennessee Oncology, PLLC — Dickson, Tennessee, United States
• Tennessee Oncology, PLLC — Franklin, Tennessee, United States
• Tennessee Oncology, PLLC — Gallatin, Tennessee, United States
• Tennessee Oncology, PLLC — Hermitage, Tennessee, United States
• Tennessee Oncology, PLLC — Lebanon, Tennessee, United States
• Florida Cancer Specialists — Altamonte Springs, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.